The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | From chemotherapy towards targeted therapies in CLL
Jennifer Woyach, MD of The Ohio State University Comprehensive Cancer Center, Columbus, OH talks about developments in chronic lymphocytic leukemia (CLL) at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Dr Woyach explains that this an exciting time for CLL as we are moving away from chemotherapy towards targeted therapies alone or in combination with expectation of good efficacy, good tolerability and hopefully long durations of remission.
